The innovation imperative: Pioneering new modalities for therapeutic leadership

Are you ready for the shift?
New therapeutic modalities—from RNA therapies to gene editing—are redefining the future of drug discovery. If you’re not adapting, you’re falling behind.
📈 By 2023, new modalities are set to account for 56% of total pipeline value. This white paper from Revvity Signals reveals how top pharma and biotech leaders are navigating this shift.
Inside, you'll learn:
Where multimodal innovation is heading next
How strategic partnerships (like Vertex + CRISPR) are breaking ground
What data strategies will set leaders apart
How to manage risk across complex R&D ecosystems
For R&D leaders, biotech founders, and pharma executives driving next-gen therapeutics.
Download the white paper now — and lead the change in drug discovery.